A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus


Diasome Pharmaceuticals




Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Study type


Funder types



DP 01-2007-01

Details and patient eligibility


A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.


6 patients




18 to 65 years old


No Healthy Volunteers

Inclusion criteria

Patients must satisfy all of the following inclusion criteria to be included in the study:

  1. be male or female between the ages of18 and 65 years, inclusive;
  2. have a current diagnosis of type 2 DM, which is currently managed with oral hypoglycemic agents for at least 3 months;
  3. have a current physical examination that reveals no clinically significant abnormalities;
  4. have no clinically significant abnormalities in vital signs;
  5. have a body mass index (BMI) <38;
  6. have a glycosylated hemoglobin (HbA1c) > 8 and <12;
  7. have a C-peptide level >3 ng/mL;
  8. have a typical fasting blood glucose levels of < 200 mg/dl (+/- 25 mg/dl);
  9. be available for the entire study period, and be able and willing to adhere to protocol requirements;
  10. if female of childbearing potential, must be using a reliable form of birth control; and,
  11. provide written informed consent prior to admission into the study.

Exclusion criteria

  1. have a history or presence of significant cardiac, gastrointestinal, endocrine, neurological, liver, or kidney disease, or conditions known to interfere with the absorption, distribution, metabolism, or excretion of insulin;

  2. have a history of drug or alcohol dependency or psychological disease;

  3. have any clinically significant illness during the 4 weeks prior to admission into the study;

  4. require regular use of medication that interferes with the absorption and/or metabolism of insulin;

  5. recent use (within 48 hours) of medications that interfere with blood glucose analyses, i.e., mannose, acetaminophen, dopamine, and ascorbic acid, which are all reported to alter glucose-oxidase type blood glucose analytical methods;

  6. use of Avandia or Actos for treating diabetes;

  7. participation in a clinical trial or use of an investigational drug within 30 days prior to admission to this study;

  8. use of MAO inhibitors or enzyme-inducing or enzyme-inhibiting agents (eg, phenobarbital or carbamazepine) within 30 days prior to admission to this study;

  9. are pregnant or lactating; 10. have an episode of severe hypoglycemia with seizure or coma within the past year;

  10. have a history of ketoacidosis;

  11. have any acute illness within 2 weeks prior to Screening; or,

  12. have elevated liver enzymes (ALT, AST, alkaline phosphatase) >1.5 times the upper limit of normal.

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems